From India to Brazil, the Astra-Oxford vaccine is key to Covid’s plans in many countries | Instant News

Trial success from Inc. and Moderna Inc. has raised hopes that a Covid-19 vaccine is coming soon. But much of the world, outside of wealthy countries like the US, is counting on other companies’ fire to get out of the crisis.

Findings from the final stage Plc vaccine studies are about to be released, and the stakes for low- and middle-income countries are huge. The shot developed with the University of Oxford accounts for more than 40% of supply to those countries, according to a deal tracked by research firm Airfinity Ltd. based in London.

The Astra vaccine costs a fraction of the price set by and will be produced in many countries, from India to Brazil. It should be easier to spread far and wide than other shots that need to be kept in very cold temperatures. But if the British counterpart cannot match the high level of efficacy and Moderna sending or releasing their inoculations rapidly, the pandemic may continue to spread death and disease in the countries that depend on it.

“There are many benefits to the Astra vaccine,” said Suerie Moon, deputy director of the Center for Global Health at the Graduate Institute for International Studies and Development in Geneva. For a low-income country, “this is huge.”

ALSO READ: Coronavirus pandemic: India’s tally hit 9.09 million with 45,209 new cases

Pfizer filed an application on Friday for authorization of emergency use in the US, and could begin rolling out in mid-December. While wealthier nations are in a position to receive their first supply of Pfizer and Moderna shots thanks to the significant numbers they have taken previously, most regions rely heavily on companies following the lead runners, especially AstraZeneca, Novavax Inc. and Johnson & Johnson. Supplies will likely struggle to keep up with demand in the months after the vaccine arrives, raising concerns about global access.

Larger population

“Most of the global population lives in low- and middle-income countries,” said Mark Eccleston-Turner, a specialist in law and infectious diseases at Keele University in the UK. “It’s not just a problem for the people there, away from us. This is a problem for most people in the world. “

A global program called Covax has made great strides in an ambitious effort to equitably distribute future vaccines around the world, getting dozens of countries to join forces and so far securing deals for 700 million doses.

reached an agreement to supply the initiative, while collaborations including the Serum Institute of India agreed to accelerate production of Astra or Novavax shots for low- and middle-income countries, at a maximum price of $ 3 per dose, with an option to secure more. A Covax agreement with Sanofi and partner GlaxoSmithKline Plc followed last month.

The program, led by the World Health Organization, the Coalition for Epidemic Preparedness Innovation and Gavi, the Vaccines Alliance, expects more deals in the coming weeks. Pfizer and BioNTech, together with Moderna, are still in talks with Covax.

easily became the most active in reaching supply deals. Of all committed volumes globally, nearly a third – about 3.2 billion doses – are set to come from British companies, according to Airfinity. More than 50 low- and middle-income countries will receive Astra and Oxford injections, in regions including Latin America, Africa, the Middle East, Asia and Eastern Europe, along with wealthy governments as well, the research group found.

If the vaccine works, meeting that demand won’t be easy. In the United Kingdom, an expected year-end shortage of injections raises doubts about how quickly AstraZeneca can immunize communities. But the company says it believes it can start supplying hundreds of millions of doses on a rolling basis once it gets approval.

Price advantage

One of the key factors behind dependence on the Astra-Oxford vaccine is the starting price. Astra says it will not profit during the pandemic and the vaccine will cost between $ 4 and $ 5 per dose, although health advocates fear what the company and others will wear when the crisis is deemed over.

The US agreed in July to get Pfizer and BioNTech vaccines in a deal that sets the price at $ 19.50 per dose, or $ 39 for immunization twice, a level BioNTech said could set a benchmark for developed countries. Moderna says it charges $ 32 to $ 37 a dose for smaller offerings and less for larger purchases.

“That price really risks making the vaccine unaffordable for many people around the world,” said Margaret Wurth, a senior researcher at Human Rights Watch in New York.

Astra-Oxford also has an over-cost advantage in terms of launching it in low- and middle-income countries. Global manufacturing coverage eases concerns about countries restricting exports, and products need to be easier to transport and store, according to Eccleston-Turner, a Keele expert.

The essential sticks can be stored at refrigerator temperature, while those from Pfizer and Moderna, based on the new messenger RNA technology, require freezing for long-term storage and transport.

ALSO READ: Moderna will charge the government $ 25- $ 37 for the Covid-19 vaccine: CEO tells paper

Because of this, many countries are looking forward to Astra’s results and are focused on the next candidates, including from China. Russia also plans to produce the Sputnik V vaccine in other countries such as India and Brazil.

“All the rich countries now have a pretty good position,” said Moon, a health specialist in Geneva. For developing countries, “it’s not as if they’re just sitting around and saying we’re going to see what flows to us. They have been aggressively going after what they can the way they have. “

(With help from Riley Griffin and Naomi Kresge.)


image source

Vaccine maker Seqirus plans to invest $ 800 million into Australia’s major manufacturing hub | Instant News

As one of the largest flu vaccine makers in the world, Seqirus is working overtime to deliver doses in the middle of an important influenza season. Even with constant demand, companies are also looking to the future – and choosing Australia as the home of an ambitious manufacturing hub.

Looking to support a 10 year supply pact with the Aussie government, Seqirus will do so Secrete $ 800 million to build a cell-based vaccine bioman manufacturing facility in Melbourne that will eventually employ more than 1,000 workers, the company said Monday.

The new plant will be located in Tullamarine in the Melbourne Airport Business Park and will be online by 2026, Seqirus said. The company did not disclose its planned footprint size in a release.

White paper

The Rise of the HPAPI Molecules – A Highly Potential API Manufacturing Trend

Powerful pharmaceutical active ingredients are increasingly on the rise in the pharmaceutical pipeline. Lonza offers all HPAPI related expertise to support your product development from concept to commercial use in an integrated manner.

The site will produce not only seasonal influenza vaccines for international use, but also shots for local Australian viruses, including antivenom for snakes, spiders and “sea creatures”, and the world’s only human vaccine against Q-Fever, a bacterial infection. spread by livestock, the company said.

The Melbourne site will complement existing production at Seqirus’ manufacturing facility in Holly Springs, North Carolina, and will also produce the key adjuvant used in some of the company’s vaccines.

RELATED: Flu vaccination maker is getting ready – and being creative – for this critical vaccination season


image source

Australia’s coronavirus vaccine holds promise in preliminary testing | News | DW | Instant News

Australia’s potential coronavirus vaccine had shown promise during initial testing, the country’s health minister Greg Hunt said on Friday.

Developed by the University of Queensland and CSL Ltd, the vaccine candidate has demonstrated an antibody response, said Hunt, as the race to develop an effective vaccine for COVID-19 heats up around the world.

Read more: COVID-19 vaccine update: Who’s ahead?

“This vaccine has been shown to be safe in phase I clinical trials and has been shown to produce a positive antibody response,” said Hunt.

“It’s doing its job. It’s especially true of the elderly, and that’s a very important outcome, given the global vulnerability of older people around the world to COVID-19.”

While the UQ and CSL vaccines are running behind some of the other vaccine candidates in terms of trials, it is set to start the final phase ahead of schedule. If it passes all the trials, it could be ready for distribution in the third quarter of next year, Hunt added.

Earlier this week, German company BioNTech and US firm Pfizer said a vaccine was co-produced 90% effective at preventing COVID-19. The announcement comes as a breakthrough in the fight against the coronavirus pandemic, which has claimed more than one million lives worldwide. The vaccine is still being tested.

Another major candidate is a viral vector vaccine that is currently being developed AstraZeneca and the University of Oxford. The results of this trial are expected soon.

see / rc (Reuters)


image source

The stance of the COVID-19 vaccine is different in Australia as experts say we are at a ‘critical time’ | Instant News

Andrea Vincita hasn’t seen her family in a year.

IT workers from Brisbane, who left them in Jakarta to move to Australia in 2013, have even given up on daily messages and video calls.

And as Australia’s strict international border policies continue, Miss Vincita understands that – at least for the foreseeable future – this will become a reality.

That is, until the COVID-19 vaccine arrives.

“I know this may be a long time coming because it needs to be disseminated throughout the world,” he said.

“My family has to be vaccinated in Indonesia, so I don’t think I will feel safe enough, or comfortable enough to meet [face to face] until that happens, even if the borders are open.

“But I’m looking forward to a vaccine so we can be safe again.”

Miss Vincita – who describes herself as very pro-vaccine – is among the majority of Australians who are ready and willing to receive injections.

But as the search for a COVID-19 vaccine increases, with researchers and pharmaceutical companies moving at an unprecedented pace, some communities are not so sure.

The exclusive data compiled by the ABC shows some doubt, with many questioning whether the vaccine is safe.

A survey of more than 2,000 people was conducted by Vox Pop Labs for ABC in late September.(ABC News)

And while a large proportion of Australians say they are willing to receive a COVID-19 vaccine, 12 percent say they are “very unlikely” or “somewhat unlikely” to receive it.

A graph shows the response to 'how likely are you to get a covid-19 vaccine when it's available?', With 64% 'very likely'
The survey results were supported by experts who said they broadly reflect the “spectrum of vaccine acceptance” in Australia.(ABC News)

Julie Leask, a social scientist at the University of Sydney who specializes in vaccine research, described the data as “fairly predictable”.

“We have a majority of Australians who are willing to receive the COVID-19 vaccine so the cup is more than half of it,” he said.

“There is [always] going to be some pretty cautious people and they want to learn more about vaccines before they really commit to it.

“And then there’s a small number who will always be against vaccination.”

A woman in a colorful top looks down at the camera near the bookshelf
Professor Leask said the “spectrum of vaccines” has nuances and ranges from advocates and acceptors, to those who are hesitant or outright averse to vaccination. (ABC News: Brendan Esposito)

Professor Leask, who has studied vaccine trends for more than two decades, said Australia – and the world – are at “a critical time now”.

“We can see greater confidence in the intention to have a COVID-19 vaccine.

“Or we can get more doubts. And a lot of things will depend on what’s happening globally, especially with what’s happening in the US and also how our governments manage. [it]. “

Efficacy and safety are very important

Communication from the Federal Government has been a key factor in public confidence around the COVID-19 vaccine.

Prime Minister Scott Morrison had to backflip in last month’s comments pointed out that he would make a coronavirus vaccine mandatory – comments the anti-vaccination group seized.

And while there is no guarantee a COVID-19 vaccine will work, or even be approved, experts have appealed to politicians and governments to stick to science to ensure a smooth rollout to ensure herd immunity.

“Scientifically, to slow down this virus and spread throughout the population, we need 60 percent of population immunity,” said Westmead Institute founder and vaccine expert Tony Cunningham.

“That means you have to have the vaccine with maximum efficacy, but you also need to convince the population to make sure we get the maximum uptake.

“The population must be assured of safety. That’s critical.”

An old man in a suit is looking at a camera in his neighborhood.
Tony Cunningham of the Westmead Institute said vaccine trials were moving “faster than I’ve seen before”.(ABC News: Brendan Esposito)

Professor Cunningham, who has been involved in vaccine research for nearly 40 years, said much of the uncertainty stems from the speed at which trials of vaccine safety and efficacy are moving.

He said these trials have historically taken at least four years is being downsized to one year.

He said critics would look for “any weakness”.

“It’s a challenging situation,” he said.

“The whole system is moving really fast.

“We are trying to adjust the urgency of the thousands and thousands of deaths in Europe and the US to make sure that we don’t take the wrong steps and have an unsafe vaccine.

The duration of the launch is still a guessing game

Locally, the Australian Government has repeatedly provided assurance that COVID-19 must pass the “rigorous assessment and approval process” of the Therapeutic Goods Administration.

And although the global vaccine race is being turned into a powerful international political weapon, no vaccine anywhere in the world has yet passed phase 3 trials.

Also as a being part of the COVAX initiativeThe Australian Government has supported the University of Queensland (UQ) vaccine candidate, which is currently in phase 1 human trials and aims to get approval by the middle of next year.

But a vaccine being developed by the University of Oxford and the medical company AstraZeneca is considered by experts to be a pioneer. The vaccine, that is The government has committed to purchasing 33.8 million doses, is currently in its final phase 3 trial.

The ABC understands Oxford will release efficacy findings in “older adults” in a matter of weeks.

However, there is still no definite timetable for when this vaccine can be launched, if approved, by Federal Budget Papers earlier this month showed launches starting July 1 next year as an “early” time frame.

Industry Minister Karen Andrews said on Sunday if the UQ or Oxford vaccines are not approved, Another global pioneer in a race can take “nine to 12 months” to be delivered in Australia, once approved.

No ‘undue pressure’

CSL, Australia’s only vaccine manufacturer, has upgraded its technology behind the scenes to locally produce the Oxford-AstraZeneca candidate and is in a separate commercial agreement with UQ.

A man in a suit and glasses outside the building
Russell Basser of Seqirus, CSL’s vaccine arm, said the company is working quickly but with safety in mind.(ABC News: Patrick Stone)

Russell Basser said the company is actively working with governments to address community concerns and ensure every vaccine is produced safely.

“We have a big task, that’s an important responsibility,” he said.

“But I don’t see any politicizing process here. There is no undue pressure on us to do something hastily – there must be pressure to do something immediately – but not by going through the normal process properly.”

Meanwhile, in her bedroom in Brisbane, Andrea Vincita hopes the trial goes smoothly so she can reunite with her family.

A woman with red and black hair from close up
Andrea Vincita said she was looking forward to seeing her friends and family visit Australia again.(ABC News: Stuart Bryce)

He said as long as he passed the phase 3 trial he would have “total confidence” in the vaccine.

“I think it’s a shortcut I don’t want to see,” he said.

“I think as long as all the information is clearly presented to the public, I hope the public will be confident enough.”


image source

Highlights of the Corona virus: Deaths in Germany pass 10,000 | Coronavirus and Covid-19 – the latest news around COVID-19 | DW | Instant News

Germany on Saturday became the sixth European country to pass a dismal 10,000 COVID-19 death toll. The country, which avoided the most severe outbreak of the first wave of the virus earlier this year, also recorded nearly 15,000 new infections.


Head of that World Health Organization, Tedros Adhanom Ghebreyesus, warned of difficult times to come for the countries of the Northern Hemisphere.

“The coming months are going to be very difficult and some countries are on a dangerous path,” the WHO director general said at a news conference on Friday, warning that the Northern Hemisphere was at a “tipping point”.

He called for immediate action, warning of an “exponential increase in cases” in many countries.

Maria Van Kerkhove, WHO’s technical chief for the coronavirus, said the WHO recorded around 445,000 new cases in the past 24 hours, nearly half in Europe. He said “ICU capacity will be reached in the coming weeks” in cities across Europe.


Former United States of America Vice President Joe Biden, who is running as a Democratic candidate for the 2020 US Presidential election, said on Friday that if he was elected president he would mandate that the vaccine be free for all Americans.

“Once we have a safe and effective vaccine, it should be free for everyone – whether you are insured or not,” Biden said in his speech, 11 days before election day.

US President Donald Trump also said vaccines should be free for Americans.

AstraZeneca said on Friday that they have continued with it WE experimental COVID-19 vaccine trial. The trial was suspended on 6 September following reports of serious neurological disease in patients during a company trial in England. The drugmaker resumed trials after the US Food and Drug Association (FDA), which monitors vaccine manufacture, said it was safe to do so.

Temporarily stopping drug and vaccine testing is very common, as studies involving thousands of participants suggest some may get sick. The US AstraZeneca study involved 30,000 people with some getting the actual vaccine and others receiving a placebo. Final testing has continued in the UK, Brazil, South Africa and Japan.

Read more: The US could see half a million deaths from coronavirus by the end of winter, the study warned

Brazil Anvisa’s regulator allowed the biomedical center to import 6 million doses of the Sinovac coronavirus vaccine, although President Jair Bolsonaro said the country would not buy China’s vaccine.

The product is currently in phase 3 trials, which were carried out with the help of a local university. It is not yet approved for widespread use in Brazil.

Brazil Pharmaceutical company Uniao Quimica said on Friday that it signed an agreement with the Russian Direct Investment Fund (RDIF) to start producing Russia’s Sputnik V vaccine next month.

This is the second agreement to produce a vaccine in Brazil, where four other vaccines have already been tested.

The Brazilian state of Bahia also signed an agreement to conduct phase 3 trials of the Sputnik V vaccine and plans to purchase 50 million doses for the northeastern Brazilian market.


German reached the bleak milestone of 10,000 coronavirus deaths since the start of the pandemic, according to figures released by the country’s Robert Koch Institute (RKI) – the government body responsible for disease control and prevention.

The number of confirmed coronavirus cases in Germany increased by 14,714 to 418,005, the RKI reported. It’s the highest number of new infections every day in the country.

A Netherlands hospitals began sending COVID-19 patients to German to reduce tension in the hospital. Flevoh Hospital in Almere, 30 kilometers (20 miles) east of Amsterdam, is sending patients to Germany by helicopter. This is the first air transport of this type from the Netherlands to Germany since the pandemic began.

Read more: Corona virus trend: The pandemic is far from over

Italy The Campania region said it would impose a lockdown to stem the flow of the coronavirus. Campania has closed most schools and imposed a curfew.

Police used tear gas in Naples to harass hundreds of people who were protesting the urge to take tougher measures. Daily cases in Italy have jumped sevenfold since early October, surging to 19,143 on Friday and raising fears that the pandemic is escalating out of control. Daily deaths also increased throughout the month, totaling 91 on Friday, but far less than the height of the first wave in the spring when the daily peak of deaths hit 900.

Italian Prime Minister Giuseppe Conte has said he wants to avoid another national lockdown that could hurt a fragile economy, but regional leaders can set their own rules when it comes to lockdowns.

Bulgaria Prime Minister Boyko Borissov and three ministers in his government will remain in isolation after the deputy ministers they contact tested positive for the virus on Friday.

Bulgarian Prime Minister Boyko Borissov was isolated on Friday after a minister tested positive

“I am awaiting orders from the health authorities and until then I will isolate myself. I last got in touch with him five days ago,” Borissov wrote in a post on his Facebook page.

Borissov said he tested negative from a test he took Friday morning before meeting US Deputy Secretary of State for Economic Growth, Energy and Environment Keith Krach.

Cases in Bulgaria have been surging since the start of the month. The country recorded 1,595 new cases as of Friday. Health authorities have banned planned operations in regions where infections exceed 120 per 100,000 people and are demanding that hospitals ensure 10% of their bed capacity is available to COVID-19 patients.

the middle East

Iran national airline IranAir resumed European flights after they were suspended due to the pandemic. A spokesman told state news agency IRNA that scheduled flights to Britain, France, Austria, Germany and Italy would resume.

kbd / dj (AP, dpa, AFP, Reuters)


image source